Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01479595 · ClinicalTrials.gov registry record · Phase 2
A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT01479595: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT01479595 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 65 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01479595, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
This study is designed to investigate the efficacy and safety of QBX258 in subjects with moderate to severe asthma.
Primary Outcome
The ACQ consists of 7 questions assessing symptoms, rescue medication use and lung function. Except for lung function (FEV1), each question was scored on a 7-point scale where 0 = no impairment and 6 = maximum impairment. Scores ranged between 0 totally controlled to 6 (severely uncontrolled). Participants with a score below 1.0 are considered to have adequately controlled asthma. Participants with a score above 1.0 were considered not to be well controlled. A negative change from baseline indic
Interventions
- DRUG Placebo
- DRUG QBX258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2012-02 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
What the finished NCT01479595 record still lists
NCT01479595 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01479595 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01479595 about?
NCT01479595 is a clinical study titled "A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma". This study is designed to investigate the efficacy and safety of QBX258 in subjects with moderate to severe asthma.
What is the current status of trial NCT01479595?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2012-02. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01479595?
The interventions under investigation include: Placebo (DRUG), QBX258 (DRUG).
Who is sponsoring clinical trial NCT01479595?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01479595's enrollment target sits among peer trials
65 987th of 2000 higher than 1,005 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia